Atamyo Therapeutics presented the first safety, pharmacodynamics, and efficacy data from its ATA-200 gene therapy in LGMD-R5 at the ASGCT 2026 Annual Meeting. Results observed in the first treated patients showed high SGCG protein expression together with improvements in several biological and functional parameters
First results presented at ASGCT 2026
Atamyo Therapeutics presented the first safety, pharmacodynamics, and efficacy results from its Phase 1b/2 clinical trial evaluating ATA-200 gene therapy in LGMD-2C/R5 limb-girdle muscular dystrophy associated with γ-sarcoglycan deficiency (SGCG, gamma-sarcoglycanopathy) at the ASGCT (American Society of Gene and Cell Therapy) Annual Meeting 2026.
Four patients with LGMD-R5 have received ATA-200 as part of the ongoing clinical trial conducted at the Powell Gene Therapy Center at the University of Florida by Dr. Barry Byrne and supported by The Dion Foundation for Children with Rare Diseases.
